Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.

Drug design, development and therapy - 1 Jan 2014

Chi Mengna, Ye Yan, Zhang Xu Dong, Chen Jiezhong

Abstract excerpt

INTRODUCTION: There is currently no curative treatment for melanoma once the disease spreads beyond the original site. Although activation of the PI3K/Akt pathway resulting from genetic mutations and epigenetic deregulation of its major regulators is known to cause resistance of melanoma to therapeutic agents, including the conventional chemotherapeutic drug dacarbazine and the Food and Drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dacarbazine
Share to Indoles
Share to Insulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-akt

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 24600206
DOI: 10.2147/DDDT.S53568
PMCID: PMC3933667

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway.PMID 24600206Read ↗

Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in MelanomaSemantic proximity Read ↗

The MAPK pathway as an apoptosis enhancer in melanomaSemantic proximity Read ↗

The AKT-p21 phosphorylation signaling axis confers poor prognosis and dacarbazine resistance in melanomaSemantic proximity Read ↗

The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt PathwaysSemantic proximity Read ↗

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.Semantic proximity Read ↗

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Semantic proximity Read ↗

RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.Semantic proximity Read ↗

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells.Semantic proximity Read ↗

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Semantic proximity Read ↗

PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.Semantic proximity Read ↗

Genetic silencing of AKT induces melanoma cell deathSemantic proximity Read ↗

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.